Literature DB >> 7738661

Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.

Z Yao1, M Zhang, H Kobayashi, H Sakahara, H Nakada, I Yamashina, J Konishi.   

Abstract

UNLABELLED: Radiolabeled streptavidin can be accumulated in tumors pretargeted with biotinylated anti-tumor antibodies. However, circulating biotinylated antibody and endogenous biotin may interfere with the tumor targeting of streptavidin. To reduce biotinylated antibody concentration in the blood, we injected avidin before streptavidin administration. The effects of avidin administration on the biodistribution and tumor targeting of radiolabeled streptavidin were examined.
METHODS: Biotinylated anti-human colon cancer monoclonal antibody (MAb) MLS128 was injected intravenously into nude mice bearing human colon cancer xenografts for pretargeting. After intraperitoneal injection of avidin, radioiodinated streptavidin was administered and its biodistribution and tumor accumulation was investigated.
RESULTS: Radioiodinated streptavidin specifically localized in the tumor pretargeted with biotinylated antibody. Avidin preadministration accelerated the tumor uptake and blood clearance of radioiodinated streptavidin. The tumor-to-blood radioactivity ratio at 6 and 24 hr after radiolabeled streptavidin injection were 1.23 +/- 0.29 and 3.04 +/- 0.86, respectively, in mice with avidin chase (mean +/- s.d., n = 7), and 0.82 +/- 0.17 and 2.29 +/- 0.29, respectively, in those without chase (mean +/- s.d., n = 7).
CONCLUSION: Localization of radiolabeled streptavidin in tumors pretargeted with biotinylated MAb could be improved by avidin chase. This approach may be useful for tumor radioimmunoimaging and radioimmunotherapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738661

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

2.  Extending Bell's model: how force transducer stiffness alters measured unbinding forces and kinetics of molecular complexes.

Authors:  Emily B Walton; Sunyoung Lee; Krystyn J Van Vliet
Journal:  Biophys J       Date:  2008-01-04       Impact factor: 4.033

3.  Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.

Authors:  Gui-Ping Li; Hui Zhang; Cheng-Mo Zhu; Jian Zhang; Xu-Feng Jiang
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

4.  Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.

Authors:  Guozheng Liu; Shuping Dou; George Mardirossian; Jiang He; Surong Zhang; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

5.  Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.

Authors:  Guozheng Liu; Shuping Dou; Xiangji Chen; Ling Chen; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

6.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

7.  Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody.

Authors:  Eric Mirallié; Catherine Saï-Maurel; Alain Faivre-Chauvet; Nicolas Regenet; Chien-Hsing Chang; David M Goldenberg; Jean-François Chatal; Jacques Barbet; Philippe Thedrez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04-30       Impact factor: 9.236

Review 8.  Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer.

Authors:  G Fleckenstein; R Osmers; J Puchta
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 9.  A semiempirical model of tumor pretargeting.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

10.  Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Authors:  John M Pagel; Yukang Lin; Nathan Hedin; Anastasia Pantelias; Donald Axworthy; Diane Stone; Don K Hamlin; D Scott Wilbur; Oliver W Press
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.